Clinical Trial Detail

NCT ID NCT03082209
Title A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AbbVie
Indications

Advanced Solid Tumor

acute myeloid leukemia

non-Hodgkin lymphoma

Therapies

ABBV-621

Age Groups: adult senior

No variant requirements are available.